Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2024-03-20 00:00:00 ET · period of report 2024-03-18 · accession 0000950170-24-034227 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-03-20 | 2024-03-18 | FDMT | Bizily Scott | CLO | M - OptEx | $7.60 | +1,750 | 2,237 | +359% | +$13.3K |
| DT | 2024-03-20 | 2024-03-18 | FDMT | Bizily Scott | CLO | S - Sale+OE | $31.27 | -1,750 | 1,737 | -50% | -$54.7K |
| DMT | 2024-03-20 | 2024-03-18 | FDMT | Bizily Scott | CLO | M - OptEx | $0.00 | -1,750 | 43.3K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-18 | M | A | 1,250 | $8.04 | 3,487 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-18 | S | D | 1,750 | $31.27 | 1,737 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-18 | M | A | 500 | $6.49 | 2,237 | D | — | — | |
| 4 | Derivative | Stock Option (Right To Buy) | 2024-03-18 | M | D | 500 | $0.00 | 16,043 | D | $6.49 · — to 2032-06-17 | 500 Common Stock | (F2) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
| 5 | Derivative | Stock Option (Right To Buy) | 2024-03-18 | M | D | 1,250 | $0.00 | 43,334 | D | $8.04 · — to 2032-08-31 | 1,250 Common Stock | (F3) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |